Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000929638-25-000809
Filing Date
2025-02-14
Accepted
2025-02-14 17:12:59
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 8800
2 JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS exhibit99-1.htm EX-99.1 7703
  Complete submission text file 0000929638-25-000809.txt   18415
Mailing Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022
Business Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 (646) 293-2100
SEELOS THERAPEUTICS, INC. (Subject) CIK: 0001017491 (see all company filings)

EIN.: 870449967 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-53409 | Film No.: 25630845
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 444 MADISON AVENUE 41ST FLOOR NEW YORK NY 10022
Business Address 444 MADISON AVENUE 41ST FLOOR NEW YORK NY 10022 646-701-7428
Lind Global Fund II LP (Filed by) CIK: 0001871665 (see all company filings)

EIN.: 863914253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A